<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00608569</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG A5234</org_study_id>
    <secondary_id>1U01AI068636</secondary_id>
    <nct_id>NCT00608569</nct_id>
  </id_info>
  <brief_title>Determining the Effects of Observed and Self-Administered Drug Regimens in HIV Infected Adults</brief_title>
  <official_title>International Trial of Modified Directly Observed Therapy Versus Self-Administered Therapy for Participants With First Virologic Failure on a Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Antiretroviral Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AIDS Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>AIDS Clinical Trials Group</source>
  <brief_summary>
    <textblock>
      Highly active antiretroviral therapy (HAART) has led to better health and survival rates
      among people with HIV/AIDS. The purpose of this study was to measure the effect of trained
      partner supervision when taking medication versus self-administered therapy in HIV infected
      participants. These participants have had their first virologic failure on a non-nucleoside
      reverse transcriptase inhibitor (NNRTI)-based HAART regimen and were starting a protease
      inhibitor (PI)-based HAART regimen at study entry.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Poor adherence to HAART is usually associated with resistant virus. Poor adherence to HAART
      can have serious consequences, including limited treatment options for HIV infected
      individuals if they become infected with resistant HIV. The purpose of this study was to
      examine the effectiveness of modified directly observed therapy (mDOT) and compare it with
      the effectiveness of self-administered therapy (non-mDOT) in HIV infected individuals with
      first virologic failure on an NNRTI-based HAART regimen who were starting a PI-based HAART
      regimen at study entry.

      mDOT was defined in this study as the daily observation of lopinavir/ritonavir (LPV/r) being
      taken on a regular basis. Observation consisted of an mDOT partner being present at the time
      the study participant took the observed dose. Half of the participants in this study were
      required to choose an mDOT partner to supervise adherence for the first 24 weeks of the
      study. Each mDOT partner completed the study-administered mDOT training program and was
      required to record all observed doses in an mDOT diary log. All participants and partners
      received health education through the study. Adherence was measured using Medication Event
      Monitoring System (MEMS) caps and self-report questionnaires.

      This study lasted 52 weeks. Per protocol, participants were to be stratified according to
      their screening viral load and the proposed study treatment. The study treatment each
      participant received was based on their treatment history. At entry, participants were to
      start one of the two PI-based HAART regimens, either FTC/Tenofovir Disoproxil Fumarate (TDF)
      200/300 mg once daily (QD) and Lopinavir/Ritonavir (LPV/RTV) 400/100 mg twice a day (BID) or
      TDF 300 mg QD and zidovudine (ZDV) 300 mg BID and LPV/RTV 400/100 mg BID. mDOT was used for
      the first 24 weeks of the study, followed by self-administration of study medications from
      week 25 to week 52. ZDV was not provided by the study. All enrolled participants except one
      who did not start study regimen initiated FTC/TDF and LPV/rtv after randomization. No
      participants started ZDV containing regimen on study. Thus, participants in this study were
      stratified by screening HIV-1 RNA only.

      There were eight visits during the study. Medical and medication history, blood collection,
      and clinical assessment were required at all visits. A quality of life questionnaire and an
      adherence tools assessment were collected at most visits. For the mDOT arm, medication diary
      logs and mDOT partner monitoring were reviewed at most visits. An mDOT exit questionnaire and
      exit interview were required at the end of the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confirmed Virologic Failure at or Prior to Week 48</measure>
    <time_frame>At or prior to Week 48</time_frame>
    <description>Confirmed virologic failure was defined as two successive HIV-1 RNA measurements at least 24 hours apart that were either:1) &lt;1 log10 copies/mL below the baseline level and &gt;400 copies/mL at the week 12 HIV-1 RNA evaluation (obtained at least 11 weeks after the date of the randomization) 2) &gt;400 copies/mL at or after the week 24 HIV-1 RNA evaluation (obtained at least 23 weeks after the date of randomization). 3) subjects who discontinued the study follow-up for any reason other than study completion, including death, and who did so ≤50 weeks after randomization was considered to be a virologic failure. Number of participants experiencing or not experiencing virologic failure at or prior to week 48 was reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Confirmed Virologic Failure at or Prior to Week 24</measure>
    <time_frame>At or prior to Week 24</time_frame>
    <description>Confirmed virologic failure was defined as two successive HIV-1 RNA measurements at least 24 hours apart that were either:1) &lt;1 log10 copies/mL below the baseline level and &gt;400 copies/mL at the week 12 HIV-1 RNA evaluation (obtained at least 11 weeks after the date of the randomization) 2) &gt;400 copies/mL at or after the week 24 HIV-1 RNA evaluation (obtained at least 23 weeks after the date of randomization). 3) subjects who discontinued the study follow-up for any reason other than study completion, including death, and who did so ≤30 weeks after randomization was considered to be a virologic failure. Number of participants experiencing or not experiencing virologic failure at or prior to week 24 was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4 Count at Follow-up Visits</measure>
    <time_frame>At Weeks 4, 12, 24, 36, and 48</time_frame>
    <description>CD4 cell count (median, inter-quartile range)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD8 Count at Follow-up Visits</measure>
    <time_frame>At week 4, 12, 24, 36, and 48</time_frame>
    <description>CD8 cell count (median, inter-quartile range)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Grade 3 or 4 Lab Event</measure>
    <time_frame>52 weeks since randomization</time_frame>
    <description>5th and 10th percentiles in weeks from randomization to first grade 3 or 4 lab event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Grade 3 or 4 Sign or Symptom</measure>
    <time_frame>52 weeks since randomization</time_frame>
    <description>5th and 10th percentiles in weeks from randomization to first grade 3 or 4 sign or symptom</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Grade 3 or 4 Lab or Sign/Symptom Event</measure>
    <time_frame>52 weeks since randomization</time_frame>
    <description>5th and 10th percentiles in weeks from randomization to first grade 3 or 4 lab or sign/ symptom event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to Second Line HAART Regimen</measure>
    <time_frame>At weeks 4, 8, 12, 24, 36, 48 and 52</time_frame>
    <description>Number of participants with self-reported 100% adherence over the week prior to study visit</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">529</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>mDOT arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral FTC/TDF+LPV/rtv or TDF+ZDV+LPV/rtv for 52 weeks. Modified directly observed therapy (mDOT) for the first 24 weeks and self-administration for the remaining 28 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-mDOT arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral FTC/TDF+LPV/rtv or TDF+ZDV+LPV/rtv for 52 weeks. Self-administration of the study treatment (non-mDOT) for 52 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir/ritonavir</intervention_name>
    <description>Two tablets (200-mg lopinavir and 50 mg ritonavir in each tablet), taken orally twice daily</description>
    <arm_group_label>mDOT arm</arm_group_label>
    <arm_group_label>non-mDOT arm</arm_group_label>
    <other_name>LPV/RTV</other_name>
    <other_name>LPV/r</other_name>
    <other_name>Kaletra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emtricitabine/Tenofovir disoproxil fumarate</intervention_name>
    <description>200-mg emtricitabine and 300 mg tenofovir disoproxil fumarate in each tablet, taken orally once daily</description>
    <arm_group_label>mDOT arm</arm_group_label>
    <arm_group_label>non-mDOT arm</arm_group_label>
    <other_name>FTC/TDF</other_name>
    <other_name>Truvada</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir disoproxil fumarate</intervention_name>
    <description>300-mg tablet taken orally once daily</description>
    <arm_group_label>mDOT arm</arm_group_label>
    <arm_group_label>non-mDOT arm</arm_group_label>
    <other_name>TDF</other_name>
    <other_name>Viread</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
    <description>300-mg tablet taken orally twice daily</description>
    <arm_group_label>mDOT arm</arm_group_label>
    <arm_group_label>non-mDOT arm</arm_group_label>
    <other_name>ZDV</other_name>
    <other_name>Retrovir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emtricitabine</intervention_name>
    <description>200-mg tablet taken orally once daily</description>
    <arm_group_label>mDOT arm</arm_group_label>
    <arm_group_label>non-mDOT arm</arm_group_label>
    <other_name>FTC</other_name>
    <other_name>Emtriva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Participants:

          -  HIV infected

          -  Have experienced or currently experiencing first baseline virologic failure on first
             NNRTI-based HAART regimen with no history of virologic failure on another regimen OR
             discontinued first NNRTI-based HAART regimen without the recommendations of clinicians
             and currently experiencing virologic failure with no history of virologic failure on
             another regimen. More information on this criterion can be found in the protocol.

          -  Confirmed virologic failure within 45 days of study entry

          -  Receiving one of the following NNRTI-based regimens for at least 16 weeks prior to
             study entry: ZDV+3TC+NVP, ZDV+3TC+EFV, d4T+3TC+NVP or d4T+3TC+EFV

          -  Able to identify a close friend, relative, or spouse who is willing to serve as a
             partner

          -  Intend to stay in current geographical area of residence for the duration of the study

          -  Agree to use LPV/rtv with MEMS caps and take the tablets out of the container only at
             dosing

          -  Willing to use acceptable forms of contraception

          -  Ability and willingness of participant or legal guardian/representative to give
             written informed consent.

          -  Required laboratory values obtained within 45 days prior to study entry.

          -  Negative serum or urine pregnancy test obtained within 48 hours prior to study entry
             for women of reproductive potential.

        Inclusion Criteria for Partners:

          -  Not a participant

          -  Friend, family member, or spouse who knows of the participant's HIV status. Partners
             do not have to live with participants.

          -  Willing to attend a 1- to 2-hour taped training session prior to study entry

          -  Willing to attend study visits with participant at study screening; entry; and Weeks
             4, 8, 12, 24, and 52

          -  Willing to directly observe participant taking at least one dose of LPV/rtv for at
             least 5 days per week for 24 weeks after stratification of participant

          -  Willing to act as a positive support for participant

          -  Willing to notify clinical staff of participant's nonadherence to study assigned
             regimen

          -  Willing to notify clinical staff if they are unable to provide mDOT for 2 weeks or
             more

          -  Willing to complete medication diary logs

          -  Willing to complete exit interview

          -  Agree to have their training session taped (if required).

          -  For mDOT arm, willing to discuss and decide with participants whether to continue mDOT
             after Week 24

          -  At least 18 years old

          -  Understand that participants have agreed to use LPV/RTV with MEMS caps and take the
             tablets out of the container only at dosing

          -  Ability and willingness to give written informed consent.

          -  No intention to relocate away from current geographical area of residence for the
             duration of study participation.

        Exclusion Criteria for Participants:

          -  Use of any immunomodulator, HIV vaccine, or other investigational therapy within 45
             days of study entry

          -  Prior treatment with any PI

          -  Previously diagnosed cancer other than basal cell carcinoma and cutaneous Kaposi's
             sarcoma

          -  Use of rifampin or rifabutin within 45 days of study entry or plan use of rifampin or
             rifabutin

          -  Requirement for taking any medications that are prohibited by this study. More
             information on this criterion can be found in the protocol.

          -  Known allergy to the study medications or their formulations

          -  Current drug or alcohol use that, in the opinion of the investigator, would interfere
             with the study

          -  Acute illness requiring hospitalization within 14 days of study entry

          -  Active tuberculosis (TB) infection

          -  Currently incarcerated

          -  Participation as a partner in this study

          -  Participation with no access to telephones

          -  Abnormal laboratory values

          -  Pregnant, breastfeeding, or intend to become pregnant

        Exclusion Criteria for Partners:

          -  A participant in this study

          -  Participation as a partner to any other participant

          -  No access to telephones

          -  Currently incarcerated
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Gross, MD, MSCE</last_name>
    <role>Study Chair</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alberto La Rosa, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Asociación Civil Impacta Salud y Educación, Peru</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gaborone Prevention/Treatment Trials CRS</name>
      <address>
        <city>Gaborone</city>
        <country>Botswana</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Pesquisa Clinica Evandro Chagas (12101)</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>21045</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Les Centres GHESKIO CRS</name>
      <address>
        <city>Bicentenaire</city>
        <state>Port-au-Prince</state>
        <zip>HT-6110</zip>
        <country>Haiti</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Miguel CRS</name>
      <address>
        <city>San Miguel</city>
        <state>Lima</state>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barranco CRS</name>
      <address>
        <city>Lima</city>
        <zip>18</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wits HIV CRS</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JCRC CRS</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kalingalinga Clinic CRS</name>
      <address>
        <city>Lusaka</city>
        <country>Zambia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ-Parirenyatwa CRS</name>
      <address>
        <city>Harare</city>
        <country>Zimbabwe</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Botswana</country>
    <country>Brazil</country>
    <country>Haiti</country>
    <country>Peru</country>
    <country>South Africa</country>
    <country>Uganda</country>
    <country>Zambia</country>
    <country>Zimbabwe</country>
  </location_countries>
  <removed_countries>
    <country>Panama</country>
  </removed_countries>
  <reference>
    <citation>Bangsberg DR, Kroetz DL, Deeks SG. Adherence-resistance relationships to combination HIV antiretroviral therapy. Curr HIV/AIDS Rep. 2007 May;4(2):65-72. Review.</citation>
    <PMID>17547827</PMID>
  </reference>
  <reference>
    <citation>Conway B. The role of adherence to antiretroviral therapy in the management of HIV infection. J Acquir Immune Defic Syndr. 2007 Jun 1;45 Suppl 1:S14-8. Review.</citation>
    <PMID>17525686</PMID>
  </reference>
  <reference>
    <citation>Goggin K, Liston RJ, Mitty JA. Modified directly observed therapy for antiretroviral therapy: a primer from the field. Public Health Rep. 2007 Jul-Aug;122(4):472-81.</citation>
    <PMID>17639650</PMID>
  </reference>
  <reference>
    <citation>Pearson CR, Micek MA, Simoni JM, Hoff PD, Matediana E, Martin DP, Gloyd SS. Randomized control trial of peer-delivered, modified directly observed therapy for HAART in Mozambique. J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):238-44.</citation>
    <PMID>17693890</PMID>
  </reference>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2008</study_first_submitted>
  <study_first_submitted_qc>January 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2008</study_first_posted>
  <results_first_submitted>September 5, 2013</results_first_submitted>
  <results_first_submitted_qc>November 14, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 15, 2013</results_first_posted>
  <last_update_submitted>November 14, 2013</last_update_submitted>
  <last_update_submitted_qc>November 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>HIV Non-Nucleoside Reverse Transcriptase Inhibitors</keyword>
  <keyword>HIV Protease Inhibitors</keyword>
  <keyword>Viral Load</keyword>
  <keyword>Virologic Failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited across 9 study sites (2 in Peru, one each in South Africa, Haiti, Uganda, Botswana, Zimbabwe, Brazil and Zambia) in the AIDS Clinical Trials Group system between April 2009 and September 2011.</recruitment_details>
      <pre_assignment_details>Five hundred twenty nine subjects including participants and partners entered the study. Among the 529 subjects, 259 were participants, which included two participants with eligibility violations. Only the 257 eligible participants were included in the analyses. All participants started TDF/FTC +LPV/rtv and stratified by screening HIV-1 RNA only.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>mDOT Arm</title>
          <description>Oral FTC/TDF+LPV/rtv or TDF+ZDV+LPV/rtv for 52 weeks. Modified directly observed therapy (mDOT) for the first 24 weeks and self-administration for the remaining 28 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Non-mDOT Arm</title>
          <description>Oral FTC/TDF+LPV/rtv or TDF+ZDV+LPV/rtv for 52 weeks. Self-administration of the study treatment (non-mDOT) for 52 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="129"/>
                <participants group_id="P2" count="128"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="119"/>
                <participants group_id="P2" count="119"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to adhere with study requirements</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Five hundred twenty nine subjects including participants and partners entered the study. Among the 529 subjects, 259 were participants, which include two participants with eligibility violations. Only the 257 eligible participants were included in the analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>mDOT Arm</title>
          <description>Oral FTC/TDF+LPV/rtv or TDF+ZDV+LPV/rtv for 52 weeks. Modified directly observed therapy (mDOT) for the first 24 weeks and self-administration for the remaining 28 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Non-mDOT Arm</title>
          <description>Oral FTC/TDF+LPV/rtv or TDF+ZDV+LPV/rtv for 52 weeks. Self-administration of the study treatment (non-mDOT) for 52 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="129"/>
            <count group_id="B2" value="128"/>
            <count group_id="B3" value="257"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="127"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.3" spread="9.7"/>
                    <measurement group_id="B2" value="39.4" spread="10.6"/>
                    <measurement group_id="B3" value="39.4" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Black Non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic (regardless of race)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Haiti</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Zambia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Botswana</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peru</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uganda</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Zimbabwe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4 Counts</title>
          <description>The baseline CD4 count is the average of screening and entry values.</description>
          <units>cells/mm3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="164" lower_limit="91" upper_limit="250"/>
                    <measurement group_id="B2" value="201" lower_limit="97" upper_limit="292"/>
                    <measurement group_id="B3" value="179" lower_limit="92" upper_limit="269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4 Count Category</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0-50 cells/mm3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>51-100 cells/mm3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>101-200 cells/mm3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>201-350 cells/mm3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>351-500 cells/mm3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;500 cells/mm3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Log10 HIV-1 RNA Viral Load</title>
          <description>The baseline HIV-1 RNA value is the result at study entry.</description>
          <units>log10 copies/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.2" lower_limit="3.8" upper_limit="4.9"/>
                    <measurement group_id="B2" value="4.3" lower_limit="3.8" upper_limit="4.9"/>
                    <measurement group_id="B3" value="4.3" lower_limit="3.8" upper_limit="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HIV-1 RNA Viral Load Category</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=400 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>401-999 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1000-9999 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10000-99999 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>100000-499999 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=500000 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Confirmed Virologic Failure at or Prior to Week 48</title>
        <description>Confirmed virologic failure was defined as two successive HIV-1 RNA measurements at least 24 hours apart that were either:1) &lt;1 log10 copies/mL below the baseline level and &gt;400 copies/mL at the week 12 HIV-1 RNA evaluation (obtained at least 11 weeks after the date of the randomization) 2) &gt;400 copies/mL at or after the week 24 HIV-1 RNA evaluation (obtained at least 23 weeks after the date of randomization). 3) subjects who discontinued the study follow-up for any reason other than study completion, including death, and who did so ≤50 weeks after randomization was considered to be a virologic failure. Number of participants experiencing or not experiencing virologic failure at or prior to week 48 was reported.</description>
        <time_frame>At or prior to Week 48</time_frame>
        <population>Two hundred fifty seven eligible participants were included in the analysis. Intent to treat analysis was performed.</population>
        <group_list>
          <group group_id="O1">
            <title>mDOT Arm</title>
            <description>Oral FTC/TDF+LPV/rtv or TDF+ZDV+LPV/rtv for 52 weeks. Modified directly observed therapy (mDOT) for the first 24 weeks and self-administration for the remaining 28 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Non-mDOT Arm</title>
            <description>Oral FTC/TDF+LPV/rtv or TDF+ZDV+LPV/rtv for 52 weeks. Self-administration of the study treatment (non-mDOT) for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Confirmed Virologic Failure at or Prior to Week 48</title>
          <description>Confirmed virologic failure was defined as two successive HIV-1 RNA measurements at least 24 hours apart that were either:1) &lt;1 log10 copies/mL below the baseline level and &gt;400 copies/mL at the week 12 HIV-1 RNA evaluation (obtained at least 11 weeks after the date of the randomization) 2) &gt;400 copies/mL at or after the week 24 HIV-1 RNA evaluation (obtained at least 23 weeks after the date of randomization). 3) subjects who discontinued the study follow-up for any reason other than study completion, including death, and who did so ≤50 weeks after randomization was considered to be a virologic failure. Number of participants experiencing or not experiencing virologic failure at or prior to week 48 was reported.</description>
          <population>Two hundred fifty seven eligible participants were included in the analysis. Intent to treat analysis was performed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Experienced Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Fisher exact test (unstratified)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.133</p_value>
            <p_value_desc>Results were considered to be statistically significant if p&lt;0.05</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Confirmed Virologic Failure at or Prior to Week 24</title>
        <description>Confirmed virologic failure was defined as two successive HIV-1 RNA measurements at least 24 hours apart that were either:1) &lt;1 log10 copies/mL below the baseline level and &gt;400 copies/mL at the week 12 HIV-1 RNA evaluation (obtained at least 11 weeks after the date of the randomization) 2) &gt;400 copies/mL at or after the week 24 HIV-1 RNA evaluation (obtained at least 23 weeks after the date of randomization). 3) subjects who discontinued the study follow-up for any reason other than study completion, including death, and who did so ≤30 weeks after randomization was considered to be a virologic failure. Number of participants experiencing or not experiencing virologic failure at or prior to week 24 was reported.</description>
        <time_frame>At or prior to Week 24</time_frame>
        <population>Two hundred fifty seven eligible participants were included in the analysis. Intent to treat analysis was performed.</population>
        <group_list>
          <group group_id="O1">
            <title>mDOT Arm</title>
            <description>Oral FTC/TDF+LPV/rtv or TDF+ZDV+LPV/rtv for 52 weeks. Modified directly observed therapy (mDOT) for the first 24 weeks and self-administration for the remaining 28 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Non-mDOT Arm</title>
            <description>Oral FTC/TDF+LPV/rtv or TDF+ZDV+LPV/rtv for 52 weeks. Self-administration of the study treatment (non-mDOT) for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Confirmed Virologic Failure at or Prior to Week 24</title>
          <description>Confirmed virologic failure was defined as two successive HIV-1 RNA measurements at least 24 hours apart that were either:1) &lt;1 log10 copies/mL below the baseline level and &gt;400 copies/mL at the week 12 HIV-1 RNA evaluation (obtained at least 11 weeks after the date of the randomization) 2) &gt;400 copies/mL at or after the week 24 HIV-1 RNA evaluation (obtained at least 23 weeks after the date of randomization). 3) subjects who discontinued the study follow-up for any reason other than study completion, including death, and who did so ≤30 weeks after randomization was considered to be a virologic failure. Number of participants experiencing or not experiencing virologic failure at or prior to week 24 was reported.</description>
          <population>Two hundred fifty seven eligible participants were included in the analysis. Intent to treat analysis was performed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Experienced Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD4 Count at Follow-up Visits</title>
        <description>CD4 cell count (median, inter-quartile range)</description>
        <time_frame>At Weeks 4, 12, 24, 36, and 48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>mDOT Arm</title>
            <description>Oral FTC/TDF+LPV/rtv or TDF+ZDV+LPV/rtv for 52 weeks. Modified directly observed therapy (mDOT) for the first 24 weeks and self-administration for the remaining 28 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Non-mDOT Arm</title>
            <description>Oral FTC/TDF+LPV/rtv or TDF+ZDV+LPV/rtv for 52 weeks. Self-administration of the study treatment (non-mDOT) for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>CD4 Count at Follow-up Visits</title>
          <description>CD4 cell count (median, inter-quartile range)</description>
          <units>cells/mm3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="212" lower_limit="129" upper_limit="309"/>
                    <measurement group_id="O2" value="219" lower_limit="158" upper_limit="289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="225" lower_limit="168" upper_limit="359"/>
                    <measurement group_id="O2" value="235" lower_limit="174" upper_limit="337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="268" lower_limit="177" upper_limit="382"/>
                    <measurement group_id="O2" value="266" lower_limit="181" upper_limit="395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="281" lower_limit="189" upper_limit="395"/>
                    <measurement group_id="O2" value="294" lower_limit="214" upper_limit="418"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="301" lower_limit="198" upper_limit="432"/>
                    <measurement group_id="O2" value="347" lower_limit="234" upper_limit="466"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD8 Count at Follow-up Visits</title>
        <description>CD8 cell count (median, inter-quartile range)</description>
        <time_frame>At week 4, 12, 24, 36, and 48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>mDOT Arm</title>
            <description>Oral FTC/TDF+LPV/rtv or TDF+ZDV+LPV/rtv for 52 weeks. Modified directly observed therapy (mDOT) for the first 24 weeks and self-administration for the remaining 28 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Non-mDOT Arm</title>
            <description>Oral FTC/TDF+LPV/rtv or TDF+ZDV+LPV/rtv for 52 weeks. Self-administration of the study treatment (non-mDOT) for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>CD8 Count at Follow-up Visits</title>
          <description>CD8 cell count (median, inter-quartile range)</description>
          <units>cells/mm3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="776" lower_limit="557" upper_limit="1048"/>
                    <measurement group_id="O2" value="859" lower_limit="557" upper_limit="1141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="895" lower_limit="625" upper_limit="1155"/>
                    <measurement group_id="O2" value="916" lower_limit="635" upper_limit="1290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="816" lower_limit="586" upper_limit="1071"/>
                    <measurement group_id="O2" value="818" lower_limit="547" upper_limit="1126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="787" lower_limit="539" upper_limit="1034"/>
                    <measurement group_id="O2" value="833" lower_limit="598" upper_limit="1131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="815" lower_limit="566" upper_limit="1037"/>
                    <measurement group_id="O2" value="823" lower_limit="573" upper_limit="1125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Grade 3 or 4 Lab Event</title>
        <description>5th and 10th percentiles in weeks from randomization to first grade 3 or 4 lab event</description>
        <time_frame>52 weeks since randomization</time_frame>
        <population>Two hundred fifty seven eligible participants were included in the analysis. As-treated analysis was performed.</population>
        <group_list>
          <group group_id="O1">
            <title>mDOT Arm</title>
            <description>Oral FTC/TDF+LPV/rtv or TDF+ZDV+LPV/rtv for 52 weeks. Modified directly observed therapy (mDOT) for the first 24 weeks and self-administration for the remaining 28 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Non-mDOT Arm</title>
            <description>Oral FTC/TDF+LPV/rtv or TDF+ZDV+LPV/rtv for 52 weeks. Self-administration of the study treatment (non-mDOT) for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Grade 3 or 4 Lab Event</title>
          <description>5th and 10th percentiles in weeks from randomization to first grade 3 or 4 lab event</description>
          <population>Two hundred fifty seven eligible participants were included in the analysis. As-treated analysis was performed.</population>
          <units>weeks</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" lower_limit="1.3">Not estimable as the upper limit for survival function at all weeks is above 95%</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="12">Not estimable as the estimates for survival function at all weeks is above 95%</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="12">Not estimable as the estimates for survival function at all weeks is above 90%</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="36.9">Not estimable as the estimates for survival function at all weeks is above 90%</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Grade 3 or 4 Sign or Symptom</title>
        <description>5th and 10th percentiles in weeks from randomization to first grade 3 or 4 sign or symptom</description>
        <time_frame>52 weeks since randomization</time_frame>
        <population>Two hundred fifty seven eligible participants were included in the analysis. As-treated analysis was performed.</population>
        <group_list>
          <group group_id="O1">
            <title>mDOT Arm</title>
            <description>Oral FTC/TDF+LPV/rtv or TDF+ZDV+LPV/rtv for 52 weeks. Modified directly observed therapy (mDOT) for the first 24 weeks and self-administration for the remaining 28 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Non-mDOT Arm</title>
            <description>Oral FTC/TDF+LPV/rtv or TDF+ZDV+LPV/rtv for 52 weeks. Self-administration of the study treatment (non-mDOT) for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Grade 3 or 4 Sign or Symptom</title>
          <description>5th and 10th percentiles in weeks from randomization to first grade 3 or 4 sign or symptom</description>
          <population>Two hundred fifty seven eligible participants were included in the analysis. As-treated analysis was performed.</population>
          <units>weeks</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.7" lower_limit="0" upper_limit="48"/>
                    <measurement group_id="O2" value="26.7" lower_limit="0.3" upper_limit="48.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="12">Not estimable as the estimates for survival function at all weeks is above 90%</measurement>
                    <measurement group_id="O2" value="48.9" lower_limit="12">Not estimable as the upper limit for survival function at all weeks is above 90%</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Grade 3 or 4 Lab or Sign/Symptom Event</title>
        <description>5th and 10th percentiles in weeks from randomization to first grade 3 or 4 lab or sign/ symptom event</description>
        <time_frame>52 weeks since randomization</time_frame>
        <population>Two hundred fifty seven eligible participants were included in the analysis. As-treated analysis was performed.</population>
        <group_list>
          <group group_id="O1">
            <title>mDOT Arm</title>
            <description>Oral FTC/TDF+LPV/rtv or TDF+ZDV+LPV/rtv for 52 weeks. Modified directly observed therapy (mDOT) for the first 24 weeks and self-administration for the remaining 28 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Non-mDOT Arm</title>
            <description>Oral FTC/TDF+LPV/rtv or TDF+ZDV+LPV/rtv for 52 weeks. Self-administration of the study treatment (non-mDOT) for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Grade 3 or 4 Lab or Sign/Symptom Event</title>
          <description>5th and 10th percentiles in weeks from randomization to first grade 3 or 4 lab or sign/ symptom event</description>
          <population>Two hundred fifty seven eligible participants were included in the analysis. As-treated analysis was performed.</population>
          <units>weeks</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" lower_limit="0" upper_limit="13.7"/>
                    <measurement group_id="O2" value="24" lower_limit="0.3" upper_limit="32.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10th percentile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" lower_limit="4.4" upper_limit="48"/>
                    <measurement group_id="O2" value="32.6" lower_limit="12">Not estimable as the upper limit for survival function at all weeks is above 90%</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adherence to Second Line HAART Regimen</title>
        <description>Number of participants with self-reported 100% adherence over the week prior to study visit</description>
        <time_frame>At weeks 4, 8, 12, 24, 36, 48 and 52</time_frame>
        <population>Only the 257 eligible participants were included in the analysis. Self-reported adherence was collected face-to-face or by self-report on the Adherence/Quality of Life/Psychosocial Interview form. Only adherence to LPV/rtv was collected.</population>
        <group_list>
          <group group_id="O1">
            <title>mDOT Arm</title>
            <description>Oral FTC/TDF+LPV/rtv or TDF+ZDV+LPV/rtv for 52 weeks. Modified directly observed therapy (mDOT) for the first 24 weeks and self-administration for the remaining 28 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Non-mDOT Arm</title>
            <description>Oral FTC/TDF+LPV/rtv or TDF+ZDV+LPV/rtv for 52 weeks. Self-administration of the study treatment (non-mDOT) for 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Adherence to Second Line HAART Regimen</title>
          <description>Number of participants with self-reported 100% adherence over the week prior to study visit</description>
          <population>Only the 257 eligible participants were included in the analysis. Self-reported adherence was collected face-to-face or by self-report on the Adherence/Quality of Life/Psychosocial Interview form. Only adherence to LPV/rtv was collected.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="129"/>
                <count group_id="O2" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114"/>
                    <measurement group_id="O2" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107"/>
                    <measurement group_id="O2" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                    <measurement group_id="O2" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>52 weeks since randomization</time_frame>
      <desc>Expedited adverse event (AE) reporting followed Intensive Division of AIDS (DAIDS) Reporting Level, which included AEs resulting in death, congenital anomalies, fetal losses, significant disabilities, requiring hospitalization, and ≥grade 3 AEs (where grade 1=mild, 2=moderate, 3=severe, 4=life threatening/disabling, 5=death).</desc>
      <group_list>
        <group group_id="E1">
          <title>mDOT Arm</title>
          <description>Oral FTC/TDF+LPV/rtv or TDF+ZDV+LPV/rtv for 52 weeks. Modified directly observed therapy (mDOT) for the first 24 weeks and self-administration for the remaining 28 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Non-mDOT Arm</title>
          <description>Oral FTC/TDF+LPV/rtv or TDF+ZDV+LPV/rtv for 52 weeks. Self-administration of the study treatment (non-mDOT) for 52 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Ruptured ectopic pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="98" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Blood bicarbonate abnormal</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Blood cholesterol</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Blood sodium increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="128"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="128"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights&quot;.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinicaltrials.gov Coordinator</name_or_title>
      <organization>Center for Biostatistics in AIDS Research, Harvard School of Public Health</organization>
      <phone>(617) 432-2829</phone>
      <email>CBAR.ClinicalTrials.Gov@sdac.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

